In the BioHarmony Drug Report Database

"Preview" Icon

Catridecacog

NovoThirteen (catridecacog) is a protein pharmaceutical. Catridecacog was first approved as NovoThirteen on 2012-09-03. It has been approved in Europe to treat inherited blood coagulation disorders.

 

Trade Name

 

NovoThirteen
 

Common Name

 

catridecacog
 

ChEMBL ID

 

CHEMBL2108282
 

Indication

 

inherited blood coagulation disorders
 

Drug Class

 

Image (chem structure or protein)

Catridecacog structure rendering